Emergent BioSolutions Inc. (EBS) - Dilution Analysis
Visualizing historical and potential share dilution over time
Dilution Analysis
Risk Assessment Details
Summary
EBS currently has 54.4M outstanding shares. with significant dilution risk as 40.2M authorized shares could dilute existing holders by 73.8%. The company has minimally diluted shareholders by 5.4% over the past 2 years.
Share Structure Timeline
Historical Data Points
| Date | Event | Outstanding | Supply |
|---|---|---|---|
| Aug 07, 2025 |
S-3 filing: Emergent Biosolutions Inc. may offer and sell, from time to time, in one or more offerings, up to $250,000,000 of our (i) shares of common stock, (ii) shares of preferred stock, (iii) warrants to purchase common stock, preferred stock, debt securities, or depositary shares, (iv) debt securities, which may be senior or subordinated, (v) depositary shares, (vi) rights to purchase common stock, preferred stock, debt securities, depositary shares or units and (vii) units that include any of these securities. |
54M | 40M |
| May 08, 2025 |
10-Q filing | 54.4M shares outstanding |
54M | 0 |
| Mar 04, 2025 |
POS AM filing: Emergent BioSolutions Inc. is offering up to 3,613,338 shares of common stock and warrants to purchase up to 2,500,000 shares of common stock by selling securityholders. |
54M | 0 |
| Mar 04, 2025 |
10-K filing | 53.0M shares outstanding |
53M | 100K |
| Dec 02, 2024 |
S-1/A filing: This S-1/A filing from Emergent BioSolutions Inc. relates to the offer and sale of common stock and warrants by selling securityholders, with the company not receiving proceeds from the sale of securities but potentially receiving proceeds from the exercise of warrants. |
54M | 7.7M |
| Nov 12, 2024 |
S-1 filing: This S-1 filing relates to the offer and sale of up to 3,613,338 shares of common stock, warrants to purchase up to 1,000,000 shares of common stock at an exercise price of $9.8802 per share (Series I Warrants) and warrants to purchase up to 1,500,000 shares of common stock at an exercise price of $15.7185 per share (Series II Warrants) by selling securityholders. |
54M | 5.2M |
| Nov 07, 2024 |
10-Q filing | 53.1M shares outstanding |
53M | 0 |
| Aug 07, 2024 |
10-Q filing | 52.6M shares outstanding |
53M | 0 |
| May 02, 2024 |
10-Q filing | 52.2M shares outstanding |
52M | 0 |
| Mar 08, 2024 |
10-K filing | 51.2M shares outstanding |
51M | 0 |
| Dec 11, 2023 |
10-Q filing | 51.8M shares outstanding |
52M | 0 |
| Aug 09, 2023 |
10-Q filing | 50.7M shares outstanding |
51M | 0 |
| May 10, 2023 |
10-Q filing | 50.2M shares outstanding |
50M | 0 |
| Mar 01, 2023 |
10-K filing | 50.1M shares outstanding |
50M | 0 |
| Nov 09, 2022 |
10-Q filing | 49.9M shares outstanding |
50M | 0 |
| Aug 02, 2022 |
10-Q filing | 50.0M shares outstanding |
50M | 0 |
| Apr 29, 2022 |
10-Q filing | 50.7M shares outstanding |
51M | 0 |
| Feb 25, 2022 |
10-K filing | 53.5M shares outstanding |
54M | 0 |
| Nov 05, 2021 |
10-Q filing | 53.7M shares outstanding |
54M | 0 |
| Jul 30, 2021 |
10-Q filing | 53.6M shares outstanding |
54M | 0 |
| Apr 30, 2021 |
10-Q filing | 53.3M shares outstanding |
53M | 0 |
| Feb 19, 2021 |
10-K filing | 53.8M shares outstanding |
54M | 0 |
| Nov 06, 2020 |
10-Q filing | 53.0M shares outstanding |
53M | 0 |
| Jul 31, 2020 |
10-Q filing | 52.6M shares outstanding |
53M | 0 |
| May 01, 2020 |
10-Q filing | 52.0M shares outstanding |
52M | 0 |
| Feb 25, 2020 |
10-K filing | 51.5M shares outstanding |
52M | 0 |